M-star

M-Star Biotechnology is a clinical-stage biopharmaceutical company focused on the development of next-generation mRNA therapeutics and vaccines. Leveraging a proprietary mRNA-LNP (lipid nanoparticle) delivery platform, the company designs highly stable and potent nucleic acid medicines for infectious diseases and oncology. Its lead programs include mRNA vaccines for COVID-19 and seasonal influenza, which aim to provide broader protection and improved safety profiles compared to first-generation products. M-Star is also expanding its pipeline into personalized cancer vaccines and protein replacement therapies. Headquartered in Suzhou, China, the company operates integrated R&D and pilot manufacturing facilities to accelerate the translation of mRNA technology into clinical applications.